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Introduction
Methotrexate (MTX) is the cornerstone disease-modifying
anti-rheumatic drug in juvenile idiopathic arthritis (JIA),
because of its efficacy. Moreover, serious adverse events
are rare. However, in Dutch patients, MTX intolerance,
defined as gastro-intestinal side effects occurring not only
after, but also before administration of MTX and when
thinking of the drug, occurred frequently. MTX intoler-
ance could lead to non-compliance and hence to
decreased efficacy, eventually resulting in the necessity to
replace it by more costly biologicals. Furthermore, it was
observed significantly more often with subcutaneous (SC)
than oral (PO) administration, contrary to widely held
views. This finding was unexpected and the question
about the choice of route of administration when starting
MTX in daily clinical practice is still unsolved.
Objectives
The aim of this study was to assess the prevalence of
MTX intolerance and its association with the route of
administration in a German cohort of JIA patients to aid
physicians in the choice of route of administration.
Methods
A cross-sectional study of JIA patients on MTX was per-
formed. Primary outcome was intolerance to MTX, which
was determined using the validated Methotrexate Intoler-
ance Severity Score (MISS) questionnaire. Clinical and
laboratory parameters, among which the route of
administration, were compared between the intolerant
and tolerant groups in univariate and multivariate
analysis.
Results
Of 179 JIA patients on MTX, 73 (40.8%) were intolerant.
Of the 46 patients who received exclusively MTX subcuta-
neous, 43.5% were intolerant versus 29.5% of 95 who
received exclusively MTX PO (P = 0.100). The former
experienced significantly more behavioural complaints
(76.1% versus 47.4%, P = 0.001) and showed a trend
towards more abdominal pain after MTX intake (43.5%
versus 27.4%, P = 0.056). Route of administration was
associated with MTX intolerance in multivariate analysis,
next to the duration of MTX use and the number of active
joints.
Conclusion
The prevalence of MTX intolerance was high. It was
higher in patients on MTX SC, but not significantly, and
they did experience more adverse effects than those on
MTX PO. Therefore, and in the light of other studies in
the field demonstrating more adverse effects in patients
on MTX SC, PO administration of MTX should be
favoured over SC administration when starting MTX.
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